Treat the Cause of Dry Eyes, not Just the Symptoms

Download Brochure

To download the brochure please fill out the form below.


This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.


WHAT IS ENVISION?

Envision by InMode enables practices to expand ocular surface care with a structured, technology-led offering designed for modern eye care. Bringing together Forma-I, Lumecca-I and Morpheus8 Prime on a single, compact platform, Envision allows clinics to address dry eye, ocular rosacea, Demodex blepharitis and periocular concerns within the existing practice setting. For practices, this supports the introduction of a dedicated service line that drives patient retention, repeat visits and sustainable revenue. For patients, Envision offers non-invasive, in-clinic procedures with minimal to no downtime, providing technology-based options that support comfort, function and confidence beyond drops and home care alone.

KEY BENEFITS

Envision is designed to support both clinical service delivery and sustainable practice growth in modern eye care settings.

  • Expands ocular surface services
    Envision enables clinics to introduce or grow in-office eyelid and ocular surface care services alongside existing optometry or ophthalmology offerings.
  • Supports repeat-visit care pathways
    Many ocular surface conditions require ongoing management. Envision supports structured treatment programs that encourage continuity of care and follow-up visits.
  • Treatments are performed within the clinic, reducing reliance on external referral for non-surgical management.
  • Compact platform design supports integration into existing rooms without major workflow disruption.
  • Positions clinics as providers of advanced, technology-assisted ocular surface care within a regulated clinical framework.

What does it mean for your patients?

  • Access to non-surgical, in-office treatment options
  • Care delivered under professional assessment and supervision
  • Treatment plans tailored to ocular presentation and condition severity
  • Programs designed to integrate with existing dry eye or eyelid hygiene management

GET IN TOUCH

CLINICAL PAPERS

Transcutaneous Radiofrequency-mediated Meibomian Gland Expression is an Effective Treatment for Dry Eye: A Prospective Cohort Trial

FREQUENTLY ASKED QUESTIONS

Envision is intended for use by qualified optometrists and ophthalmologists, operating within their scope of practice.

Envision may be incorporated into management plans for ocular surface and eyelid conditions such as dry eye disease, meibomian gland dysfunction and ocular rosacea, subject to clinical assessment.

No. Envision supports non-surgical, in-office treatments and does not replace surgical intervention where surgery is clinically indicated.

Most Envision treatments do not involve interruption to daily activities. Individual responses vary depending on modality used and patient factors.

Envision supports ROI by enabling:

  • Expansion of in-office ocular surface services
  • Repeat-visit treatment programs
  • Improved patient retention through ongoing care pathways
  • Efficient use of clinic space and staff resources

DO YOU have QUESTIONS ?

If you have any questions regarding any of our technologies, treatments or anything in general, we’re here to help! Please do not include any sensitive personal data (such as patient photos or health information) when submitting this form.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.